Clinical Trial Update: A Study of AK-01 (LY3295668) in Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A two-phase clinical trial evaluating AK-01 (LY3295668) in solid tumors has completed phases 1 and 2 with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Head and Neck Neoplasms
• Neoplasm Metastasis
• Neoplasms
• Small Cell Lung Carcinoma
• Solid Tumor
• Triple Negative Breast Neoplasms

Drugs mentioned

• AK-01 (LY3295668) (LY3295668)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neoplasms, Neoplasm Metastasis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-02